Sun Pharmaceutical Industries officially announced here on Wednesday that it has reported a consolidated net profit of Rs 3,117.95 crore in the second quarter of FY26, registering a growth of 2.55% from Rs 3,040.16 crore in the year-ago period.

According to an official statement, the company’s total revenue from operations in Q2FY26 increased by almost 9% to Rs 14,478.31 crore from Rs 13,291.39 crore, on an year-on-year (YoY) basis.

Advertisement

The company reported an EBITDA of Rs 4,527.1 crore during the September quarter, recording a 14.9% YoY growth, with an EBITDA margin of 31.3%.

Sun Pharmaceutical Industries Managing Director Kirti Ganorkar said, “India, emerging markets and the rest of the world led our growth for the period. US sales of innovative medicines surpassed generics

See Full Page